Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (≤2 cm in diameter) from arterial enhancing pseudolesions: Special emphasis on hepatobiliary phase imaging

Investigative Radiology

Volumn 45, Issue 2, 2010, Pages 96-103

  Sun, Hye Young ^a   Lee, Jeong Min ^a   Shin, Cheong Ii ^a   Lee, Dong Ho ^a   Moon, Sung Kyoung ^a   Kim, Kyung Won ^a   Han, Joon Koo ^a   Choi, Byung Ihn ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Arterial enhancingpseudolesions; CT; Hepatocellular carcinoma; Liver; MRI

Indexed keywords

DOXORUBICIN; GADOXETIC ACID; IODINATED POPPYSEED OIL; IOPROMIDE;

ADULT; AGED; ARTERY LESION; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER ANGIOGRAPHY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TUMOR DIFFERENTIATION; TUMOR VOLUME;

EID: 74949142562     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3181c5faf7     Document Type: Article

References (35)

1. Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153-156. (Pubitemid 32911406)
2. Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology. 2008;47:97-104.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236.
4. Semelka RC, Martin DR, Balci C, et al. Focal liver lesions: comparison of dual-phase CT and multisequence multiplanar MR imaging including dynamic gadolinium enhancement. JMagn Reson Imaging. 2001;13:397-401.
5. Hussain SM, Semelka RC. Hepatic imaging: comparison of modalities. Radiol Clin North Am. 2005;43:929-947, ix.
6. Willatt JM, Hussain HK, Adusumilli S, et al. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology. 2008;247:311-330.
7. Lee DH, Kim SH, Lee JM, et al. Diagnostic performance of multidetector row computed tomography, superparamagnetic iron oxide-enhanced magnetic resonance imaging, and dual-contrast magnetic resonance imaging in predicting the appropriateness of a transplant recipient based on milan criteria: correlation with histopathological findings. Invest Radiol. 2009;44:311-321.
8. Zech CJ, Vos B, Nordell A, et al. Vascular enhancement in early dynamic liver MR imaging in an animal model: comparison of two injection regimen and two different doses Gd-EOB-DTPA (gadoxetic acid) with standard Gd-DTPA. Invest Radiol. 2009;44:305-310.
9. Yoon MA, Kim SH, Park HS, et al. Value of dual contrast liver MRI at 3.0 T in differentiating well-differentiated hepatocellular carcinomas from dysplastic nodules: preliminary results of multivariate analysis. Invest Radiol. 2009;44:641-649.
10. Burrel M, Llovet JM, Ayuso C, et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology. 2003;38:1034-1042.
11. Hwang SH, Yu JS, Kim KW, et al. Small hypervascular enhancing lesions on arterial phase images of multiphase dynamic computed tomography in cirrhotic liver: fate and implications. JComput Assist Tomogr. 2008;32:39-45.
12. Kanematsu M, Kondo H, Semelka RC, et al. Early-enhancing non-neoplastic lesions on gadolinium-enhanced MRI of the liver. Clin Radiol. 2003;58:778-786.
13. Kim TK, Choi BI, Han JK, et al. Nontumorous arterioportal shunt mimicking hypervascular tumor in cirrhotic liver: two-phase spiral CT findings. Radiology. 1998;208:597-603.
14. Shimizu A, Ito K, Koike S, et al. Cirrhosis or chronic hepatitis: evaluation of small (<2 cm) early-enhancing hepatic lesions with serial contrast-enhanced dynamic MR imaging Radiology 2003 226 550-555
15. Yu JS, Kim KW, Jeong MG, et al. Nontumorous hepatic arterial-portal venous shunts: MR imaging findings. Radiology. 2000;217:750-756.
16. Huppertz A, Balzer T, Blakeborough A, et al. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology. 2004;230:266-275.
17. Halavaara J, Breuer J, Ayuso C, et al. Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT-a multicenter trial. J Comput Assist Tomogr. 2006;30:345-354.
18. Lee MW, Lee JM, Lee JY, et al. Preoperative evaluation of the hepatic vascular anatomy in living liver donors: comparison of CT angiography and MR angiography. J Magn Reson Imaging. 2006;24:1081-1087.
19. Itoh S, Ikeda M, Achiwa M, et al. Late-arterial and portal-venous phase imaging of the liver with a multislice CT scanner in patients without circulatory disturbances: automatic bolus tracking or empirical scan delay? Eur Radiol. 2004;14:1665-1673.
20. Park SH, Cho YK, Ahn YS, et al. Local recurrence of hepatocellular carcinoma after segmental transarterial chemoembolization: risk estimates based on multiple prognostic factors. Korean J Radiol. 2007;8:111-119.
21. Bolondi L, Gaiani S, Celli N, et al. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology. 2005;42:27-34.
22. Jeong YY, Mitchell DG, Kamishima T. Small Krinsky GA, Lee VS.MR imaging of cirrhotic nodules.Abdom Imaging.2000;25:471-482
23. Krinsky GA, Lee VS. MR imaging of cirrhotic nodules. Abdom Imaging. 2000;25:471-482.
24. Brancatelli G, Baron RL, Peterson MS, et al. Helical CT screening for hepatocellular carcinoma in patients with cirrhosis: frequency and causes of false-positive interpretation. Am J Roentgenol. 2003;180:1007-1014.
25. Holland A, Hecht E, Hahn W, et al. Importance of small Yu JS, Kim KW, Sung KB, et al.Small arterial-portal venous shunts: a cause of pseudolesions at hepatic imaging.Radiology.1997;203:737-742
26. Yu JS, Kim KW, Sung KB, et al. Small arterial-portal venous shunts: a cause of pseudolesions at hepatic imaging. Radiology. 1997;203:737-742.
27. Yu JS, Lee JH, Chung JJ, et al. Small hypervascular hepatocellular carcinoma: limited value of portal and delayed phases on dynamic magnetic resonance imaging. Acta Radiol. 2008;49:735-743.
28. Reimer P, Schneider G, Schima W. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol. 2004;14:559-578.
29. Tamada T, Ito K, Sone T, et al. Dynamic contrast-enhanced magnetic resonance imaging of abdominal solid organ and major vessel: comparison of enhancement effect between Gd-EOB-DTPA and Gd-DTPA. J Magn Reson Imaging. 2009;29:636-640.
30. Libra A, Fernetti C, Lorusso V, et al. Molecular determinants in the transport of a bile acid-derived diagnostic agent in tumoral and nontumoral cell lines of human liver. J Pharmacol Exp Ther. 2006;319:809-817.
31. Kim JI, Lee JM, Choi JY, et al. The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Invest Radiol. 2008;43:202-210.
32. Kim YK, Kim CS, Chung GH, et al. Comparison of gadobenate dimeglu-mine-enhanced dynamic MRI and 16-MDCT for the detection of hepatocel-lular carcinoma. Am J Roentgenol. 2006;186:149-157.
33. Marin D, Di Martino M, Guerrisi A, et al. Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate dimeglu-mine-enhanced MR imaging and multiphasic 64-section CT. Radiology. 2009;251:85-95.
34. Mori K, Yoshioka H, Itai Y, et al. Arterioportal shunts in cirrhotic patients: evaluation of the difference between tumorous and nontumorous arterioportal shunts on MR imaging with superparamagnetic iron oxide. Am J Roentgenol. 2000;175:1659-1664.
35. Choi D, Mitchell DG, Verma SK, et al. Hepatocellular carcinoma with indeterminate or false-negative findings at initial MR imaging: effect on eligibility for curative treatment initial observations. Radiology. 2007; 244:776-783.